Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Health
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
The Pharmalot View
STAT+

When should drugmakers go all in and cut off essential medicines to Russia?

  • Ed Silverman

By Ed Silverman March 19, 2022

Reprints
A woman walks past a pharmacy in Moscow in 2020. ALEXANDER NEMENOV/AFP via Getty Images

Just say nyet?

As the war in Ukraine intensifies, several of the world’s largest pharmaceutical companies have now joined hundreds of corporations in other industries that are cutting ties to Russia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed covers the pharmaceutical industry.

Tags

Create a display name to comment

This name will appear with your comment

Trending
cytokine storm cell signalling
FDA rejects antidepressant seen as possible Covid-19 treatment
FDA rejects antidepressant seen as possible Covid-19 treatment
acute flaccid myelitis micrograph
Puzzling pediatric hepatitis cases echo an earlier mysterious illness
Puzzling pediatric hepatitis cases echo an earlier mysterious illness
What the current spike in Covid-19 cases could say…
What the current spike in Covid-19 cases could say about the coronavirus’ future
Recommended
Diversity in clinical trials concept
National Academies report cites ‘urgent’ need to recruit more…
National Academies report cites ‘urgent’ need to recruit more diverse participants for clinical trials
Pharmalittle: FDA declines to approve old antidepressant for Covid;…
Pharmalittle: FDA declines to approve old antidepressant for Covid; U.S.-China trade fight may derail WTO Covid…
Pills dollar QALY
Two dozen states side with HHS in its raucous…
Two dozen states side with HHS in its raucous dispute with pharma over a drug discount…

Recommended Stories

Diversity in clinical trials concept
Health

National Academies report cites ‘urgent’ need to recruit more diverse participants for clinical trials

By Usha Lee McFarling

Exclusive

Senate FDA legislation will include dietary supplement, cosmetic reforms

By Nicholas Florko

Biotech

Police reports detailing Seagen CEO’s arrest raise questions about biotech’s response

By Damian Garde

Roche HQ
Biotech

Roche anti-TIGIT cancer immunotherapy fails second clinical trial, raising doubts about drug class

By Adam Feuerstein

Biotech

A new biotech investment firm, headed by a pair of noteworthy VCs, seeks to ‘free the founders’

By Allison DeAngelis